MS News That Caught My Eye Last Week: Mavenclad, Sativex, Mistreatment, Patient Survey

Ed Tobias avatar

by Ed Tobias |

Share this article:

Share article via email
banner for

Trial Will Test Mavenclad for Advanced Progressive MS

I often think that researchers have forgotten about people whose MS has progressed to an advanced stage. But MS patients who have moved into a wheelchair deserve treatment with a disease-modifying therapy as much as those who are just beginning their MS journey. So, bravo to these scientists for their efforts. It’s a shame that this trial is limited to the U.K., but at least it’s something.

After some delays due to the COVID-19 pandemic, the Phase 2/3 clinical trial evaluating whether Mavenclad (cladribine) can slow the worsening of hand and arm function in adults with progressive multiple sclerosis (MS) and very limited walking abilities, has recruited its first patient.

The study, ChariotMS (NCT04695080), aims to enroll up to 200 patients with advanced progressive MS — a population typically excluded from clinical trials — at 20 sites across the U.K. More information about contacts and locations is available here.

Click here or on the headline to read the full story.

Recommended Reading
variable temperatures and hot weather/multiplesclerosisnewstoday.com/link with more hospital visits

Heat, Variable Temperatures Found to Increase Risk of MS Hospital Visits

***

Third Phase 3 Trial of Sativex, Cannabis Extract for MS Spasticity, Planned

I’ve seen a lot of interest among the patient community in the Sativex spray, and I recently wrote a column about it. Jazz Pharmaceuticals already has various studies underway, including a small study in Brussels, which reported encouraging results. Sativex already is available in 25 countries, including most of Europe and Canada, but not in the U.S. Let’s hope all of this research leads to an approval here soon.

Jazz Pharmaceuticals is planning to open a third Phase 3 clinical trial of Sativex (nabiximols), an oral spray that contains cannabis extracts, as an add-on treatment for people with multiple sclerosis (MS) and spasticity, the company announced.

Set to start this year, the RELEASE MSS5 trial (NCT04984278) is expected to enroll about 190 adults with any type of MS and spasticity (muscle stiffness and spasms). While study sites are yet to be announced, contact information is available here.

Click here or on the headline to read the full story.

***

Many MS Patients Report Mistreatment by Caregivers

Back in February, I wrote about a study reporting that people with MS were mistreated by family or friends who care for them. This study, also conducted by a branch of the University of California, has reached similar findings. The most common type of abuse was psychological, followed by patient neglect. To a lesser extent were reports of financial, physical, and sexual abuse.

More than half of people with multiple sclerosis (MS) who require an informal caregiver have experienced abuse or mistreatment by that caregiver, according to a study conducted in California.

The study, “Validity and Reliability of the Scale to Report Emotional Stress Signs–Multiple Sclerosis (STRESS-MS) in Assessing Abuse and Neglect of Adults with Multiple Sclerosis,” was published in the International Journal of MS Care.

Click here or on the headline to read the full story.

***

US Survey Finds High Rates of Dissatisfaction With Quality of Life, But Satisfaction With Healthcare

I’m surprised that only 40% of people with MS are dissatisfied to some extent with the quality of their lives, according to this survey. I thought this number would be much higher. I’ve lived with MS for over 40 years, and although I think I’ve had a really good life, I’m certainly dissatisfied with some aspects of it.

I’m also surprised that more than 70% of people with MS report being satisfied with their health insurance and treatment plans. That’s not what I read on the MS social media sites I follow. I think there’s a lot more dissatisfaction with a lack of insurance coverage, particularly for medications, and with a lack of MS knowledge and patient skills by many neurologists. What do you think?

More than one-third of people with multiple sclerosis (MS) who responded to an online U.S.-based survey are dissatisfied with their quality of life, and more than one in four MS patients are pessimistic about their future, according to the results of the survey, conducted by Multiple Sclerosis News Today.

Nonetheless, the findings show that about three-quarters of the MS patients surveyed are satisfied with their treatment plan as well as with their health insurance, and four out of five are not considering changing their medication.

Click here or on the headline to read the full story.

***

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, Bionews, and are intended to spark discussion about issues pertaining to multiple sclerosis.

Comments

Carol Allen avatar

Carol Allen

Hi Ed
It was great to read about the ChariotMS trial in the UK, on you website. My name is Carol and I’m the very first patient to be enrolled on the trial. I’m now an electric wheelchair user and feel I’m part of a group that is written off because I cannot walk! I feel this is a great opportunity that I can’t miss. I’m hoping to maintain my upper body strength, so I can stay as independent as possible. I’ve tried all sorts of alternative treatments over the years, so now I’m hoping scientists can help. I’m so pleased information about the ChariotMS has reached the US!

Reply
Ed Tobias avatar

Ed Tobias

Hi Carol,

I was happy to spread the world. I think research overlooks too many people with MS...primarily aiming for young, newly diagnosed folks. Congrats on being the first to enroll and I wish you great success.

Ed

Reply
Jenny Ferguson avatar

Jenny Ferguson

Congratulations Carol, good news . I’m hoping to be recruited too, this could be a game changer so everything crossed . Xx

Reply

Leave a comment

Fill in the required fields to post. Your email address will not be published.